Dr Reddys Laboratories (RDY) Operating Leases (2021 - 2026)

Dr Reddys Laboratories' Operating Leases history runs 6 years deep, the most recent figure standing at $133.5 million for Q1 2026.

• In Q1 2026, Operating Leases rose 184.44% year-over-year to $133.5 million; the TTM figure through Mar 2026 stood at $133.5 million (up 184.44% YoY), while the FY2026 annual figure was $138.3 million, up 187.54% from the prior year.
• Operating Leases was $133.5 million for Q1 2026 at Dr Reddys Laboratories, up from $46.9 million in the prior quarter.
• In the past five years, Operating Leases ranged from a high of $133.5 million in Q1 2026 to a low of $5.3 million in Q3 2023.
• Historically, Operating Leases has averaged $42.3 million across 5 years, with a median of $26.1 million in 2024.
• The sharpest annual moves came in 2023 and 2026: Operating Leases sank 39.93% in 2023, then jumped 184.44% in 2026.
• A 5-year view of Operating Leases shows it stood at $25.9 million in 2022, then tumbled by 79.43% to $5.3 million in 2023, then jumped by 395.45% to $26.4 million in 2024, then jumped by 77.97% to $46.9 million in 2025, then jumped by 184.44% to $133.5 million in 2026.
• The last three Operating Leases figures came in at $133.5 million (Q1 2026), $46.9 million (Q1 2025), and $26.4 million (Q1 2024), per Business Quant data.